Skip to main content

Advertisement

SpringerLink
Log in

Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA)

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

  2. Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13:233–241.

  3. Böckelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol. 2015;54:5–16.

  4. Parent P, Cohen R, Rassy E, et al. A comprehensive overview of promising biomarkers in stage II colorectal cancer. Cancer Treat Rev. 2020;88:102059.

  5. Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832–41.

  6. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra392.

Download references

Acknowledgement

Research funding was provided to MD Anderson by BioNtech AG, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Immatics, and Pfizer.

Author information

Authors and Affiliations

  1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Building 10, Room 4-3740, Bethesda, MD, 20892, USA

    Emily A. Verbus MD, Alexander J. Rossi MD, Allen J. Luna BE & Jonathan M. Hernandez MD

  2. Section of Colorectal Surgery, Division of Surgery, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA

    Atif Iqbal MD

  3. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Van K. Morris MD

Authors
  1. Emily A. Verbus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander J. Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allen J. Luna BE
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atif Iqbal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Van K. Morris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Van K. Morris MD or Jonathan M. Hernandez MD.

Ethics declarations

Disclosure

Dr. Van K. Morris serves as a consultant and advisor for Array BioPharma, Axiom Healthcare Strategies, Bicara Therapeutics, BioMedical Insights, Boehringer Ingelheim, Incyte, Pfizer, and Servier.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 145 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Verbus, E.A., Rossi, A.J., Luna, A.J. et al. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). Ann Surg Oncol 28, 4095–4097 (2021). https://doi.org/10.1245/s10434-021-10112-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10112-z

Search

Navigation